Danish scientists have good news for millions of tuberculosis patients. A vaccine has been developed by a team of scientists, at the Statens Serum Institute in Copenhagen, which can cure the disease both in active and latent state of the infection.

Though a meager 5% develops the symptoms after the infection, once the Mycobacterium tuberculosis enters the body, it is reported to alter its chemical composition and starts living in a dormant state.

Although BCG has been recommended by health officials to treat TB, those drugs are inaccessible in most of the developing countries. Such revelation has created an alarming situation in the whole world.

Professor Peter Davies, secretary of the group TB Alert reportedly claimed this as a major breakthrough in the case of TB treatment, as the vaccine can provide the immunity before as well as the after the bacteria attacks the body.

As if now, doctors have been advising BCG to contain the disease at an early stage, the newly developed vaccine seems to be more effective in terms of results.

With the global surge of TB cases, Professor Francis Drobniewski, Director of the Health Protection Agency's National Mycobacterium Reference Laboratory has welcomed the new vaccine as the novel development in the field of drug industry.